Cabaletta Bio, Inc.
CABA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001759138
No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $490.4M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Cabaletta Bio, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 84 | 1 | 97 | +14 |
| Shares | 36.4M | 800 | 40.9M | +4.46M (+12.3%) |
| Value | $470.5M | $11.0K | $622.6M | +$152.1M (+32.3%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (26)
Institutions that held Cabaletta Bio, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (12)
Institutions that held Cabaletta Bio, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Boxer Capital, LLC | 540,000 | $6.97M |
| Blackstone Group Inc. | 498,779 | $6.44M |
| Millennium Management LLC | 371,070 | $4.79M |
| Affinity Asset Advisors, LLC | 125,000 | $1.61M |
| Marshall Wace, LLP | 85,696 | $1.11M |
| Renaissance Technologies LLC | 77,700 | $1.00M |
| Gsa Capital Partners LLP | 38,919 | $502.0K |
| Veritable, L.P. | 37,245 | $480.8K |
| American Century Companies Inc | 13,873 | $179.1K |
| Foster Dykema Cabot & Co Inc | 309 | $4.00K |
| Impact Partnership Wealth, LLC | 273 | $3.52K |
| NewSquare Capital LLC | 10 | $129 |
Not filed for Q3 2023 yet (1)
Institutions that held Cabaletta Bio, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Endurance Wealth Management, Inc. | 800 | $11.0K |